Dr Kelly Gillespie joins Ethics Talk to discuss her article, coauthored with Dr Taleed El-Sabawi: “When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond?”
New guidelines and the continuous modification of current policies will be needed in order to establish and maintain an appropriate professional relationship between physicians and pharmaceutical companies.
The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.
Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
Professor Rebecca Feinberg joins Health By Law to discuss the Alabama Supreme Court decision in LePage v Center for Reproductive Medicine and the legal, clinical, and ethical implications of embryonic personhood.
Two physicians assert that pharmaceutical companies' sponsorship of clinical conferences for residents and physicians represent a conflict of interest.
Two physicians assert that pharmaceutical companies' sponsorship of clinical conferences for residents and physicians represent a conflict of interest.
The ethical questions surrounding the recruitment of patients for clinical trials become more complicated when the recruiting physicians receive financial benefits for each patient enrolled.
Murray Kopelow, chief executive of the Accreditation Council for Continuing Medical Education, discusses his organization's the new draft standards for commercial support of continuing medical education.
The financial generosity of the pharmaceutical industry to provide funding for medical education tempts a compromise of professional standards and ethics.